- Germany
- /
- Healthcare Services
- /
- XTRA:V3V
Earnings Miss: VITA 34 AG Missed EPS By 29% And Analysts Are Revising Their Forecasts
VITA 34 AG (ETR:V3V) missed earnings with its latest full-year results, disappointing overly-optimistic forecasters. Results showed a clear earnings miss, with €20m revenue coming in 2.6% lower than what the analystsexpected. Statutory earnings per share (EPS) of €0.37 missed the mark badly, arriving some 29% below what was expected. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.
View our latest analysis for VITA 34
Taking into account the latest results, the current consensus from VITA 34's dual analysts is for revenues of €22.0m in 2021, which would reflect a notable 9.6% increase on its sales over the past 12 months. Per-share earnings are expected to soar 27% to €0.47. In the lead-up to this report, the analysts had been modelling revenues of €22.3m and earnings per share (EPS) of €0.61 in 2021. So there's definitely been a decline in sentiment after the latest results, noting the pretty serious reduction to new EPS forecasts.
It might be a surprise to learn that the consensus price target was broadly unchanged at €21.00, with the analysts clearly implying that the forecast decline in earnings is not expected to have much of an impact on valuation.
These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the VITA 34's past performance and to peers in the same industry. The analysts are definitely expecting VITA 34's growth to accelerate, with the forecast 9.6% annualised growth to the end of 2021 ranking favourably alongside historical growth of 6.5% per annum over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 4.8% per year. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect VITA 34 to grow faster than the wider industry.
The Bottom Line
The most important thing to take away is that the analysts downgraded their earnings per share estimates, showing that there has been a clear decline in sentiment following these results. Happily, there were no major changes to revenue forecasts, with the business still expected to grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.
With that in mind, we wouldn't be too quick to come to a conclusion on VITA 34. Long-term earnings power is much more important than next year's profits. At least one analyst has provided forecasts out to 2025, which can be seen for free on our platform here.
It is also worth noting that we have found 1 warning sign for VITA 34 that you need to take into consideration.
If you’re looking to trade VITA 34, open an account with the lowest-cost* platform trusted by professionals, Interactive Brokers. Their clients from over 200 countries and territories trade stocks, options, futures, forex, bonds and funds worldwide from a single integrated account. Promoted
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
*Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
About XTRA:V3V
VITA 34
Engages in the collection, processing, cryopreservation, and storage of stem cells from umbilical cord blood and tissue and postnatal tissue in Germany, Poland, Portugal, and internationally.
Adequate balance sheet with moderate growth potential.